What is the recommended management for morphea?

Morphea Treatment

For active, potentially disfiguring or disabling morphea, treat with oral or subcutaneous methotrexate at 15 mg/m²/week combined with systemic corticosteroids (prednisone 1 mg/kg/day, maximum 50 mg) for the first 3 months, then continue methotrexate alone for at least 12 months after achieving clinical remission. 1

Treatment Algorithm by Disease Severity

Limited/Circumscribed Morphea (Superficial, Non-Progressive)

For isolated, superficial plaques that are primarily cosmetic concerns:

• First-line: High-potency topical corticosteroids 2
• Alternative topical options: Tacrolimus, calcipotriol, or imiquimod 5% cream 1
  • Imiquimod works by upregulating interferon α and γ, which inhibit collagen production by downregulating transforming growth factor beta 1
• Phototherapy: Medium-dose UVA1 (50 J/cm²) phototherapy 5 times weekly for 8 weeks may improve skin softness 1
  • Narrowband UVB is an alternative with similar efficacy but causes less tanning than UVA1 3
  • Caveat: Phototherapy requires prolonged maintenance with high cumulative radiation doses, raising concerns about long-term skin aging and carcinogenesis, especially in children 1

Active, Potentially Disfiguring or Disabling Morphea

This includes linear scleroderma, generalized morphea, deep morphea, and mixed subtypes:

Systemic therapy is mandatory 1:

1. Methotrexate 15 mg/m²/week (oral or subcutaneous, maximum 20 mg)

   • This is the only treatment with Level 1b evidence (randomized controlled trial) showing efficacy 1
   • Achieves 2.31 times higher global improvement compared to corticosteroids alone (NNT = 3) 3

2. Plus prednisone as "bridge therapy":

   • 1 mg/kg/day (maximum 50 mg) as single morning dose
   • Continue for 3 months, then taper over 1 month until discontinuation 1
   • Corticosteroids are useful only in the active inflammatory phase 1

3. Duration: Continue methotrexate for at least 12 months after achieving clinical remission before considering tapering 1

   • Prolonged remission off medication is more likely with treatment duration >12 months 1

Expected adverse events with methotrexate: Alopecia, nausea, headache, fatigue, transient hepatotoxicity (generally mild and well-tolerated) 3. Prednisone may cause weight gain >5% and striae rubrae 3.

Refractory or Methotrexate-Intolerant Disease

Second-line: Mycophenolate mofetil 500-1000 mg/m² 1, 2

• Use when methotrexate is ineffective, disease relapses after remission, or patient is methotrexate-intolerant
• Retrospective data shows clinical improvement in all patients with severe refractory disease, with good safety profile 1
• Alternative second-line options: Mycophenolic acid or abatacept 2

Severe Refractory Disease

For cases failing standard therapy, consider:

• Biologics (TNF or IL-6 inhibitors) 1
• JAK inhibitors (topical ruxolitinib 1.5% has shown success in localized recalcitrant disease) 4
• Cyclophosphamide 1
• IVIG 5

Note: These lack high-level evidence but are used in clinical practice for resistant or CNS disease 1

Critical Assessment Considerations

Before initiating treatment, determine:

1. Disease activity vs. damage: Only active inflammatory disease responds to treatment 1, 6

   • Use validated tools like LoSCAT (Localized Scleroderma Cutaneous Assessment Tool) 1

2. Subtype classification: Linear scleroderma, generalized morphea, circumscribed morphea, pansclerotic morphea, or mixed 1

3. Extracutaneous involvement:

   • Ophthalmological assessment (including uveitis screening) is mandatory at diagnosis for all patients, especially with face/scalp lesions 1
   • Assess for fascia, muscle, joint, and bone involvement in linear forms 7

4. Referral: Given disease rarity (3.4 cases per million children/year), refer suspected cases to specialized centers 1

Common Pitfalls

• Starting methotrexate without corticosteroids: The combination is more effective than either alone during the initial inflammatory phase 1
• Stopping methotrexate too early: Must continue ≥12 months after remission to prevent relapse 1
• Using phototherapy in children without considering long-term risks: High cumulative radiation doses raise carcinogenesis concerns 1
• Treating inactive/damage-only disease with immunosuppression: Treatment only works in inflammatory/active disease 6
• Not screening for uveitis: Mandatory ophthalmological assessment, especially with facial involvement 1

Adjunctive Measures

• Physiotherapy for functional impairment 5
• Psychiatric counseling for psychological impact 5
• Autologous fat grafting or adipose-derived stem cell transplantation for soft tissue defects once disease is inactive 5, 2